Discounted Cash Flow (DCF) Analysis Levered
ASLAN Pharmaceuticals Limited (ASLN)
$1.85
-0.07 (-3.65%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | - | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
Share price | $ 1.85 |
---|---|
Beta | 1.757 |
Diluted Shares Outstanding | 13.95 |
Cost of Debt | |
Tax Rate | -0.19 |
After-tax Cost of Debt | 9.77% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 12.917 |
Total Debt | 37.62 |
Total Equity | 25.81 |
Total Capital | 63.43 |
Debt Weighting | 59.31 |
Equity Weighting | 40.69 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | - | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
WACC | ||||||||||
PV LFCF | - | - | - | - | - | - | - | - | ||
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 11.05 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -19.28 |
Equity Value | - |
Shares Outstanding | 13.95 |
Equity Value Per Share | - |